Acarix A/S (ACARIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Acarix A/S (ACARIX) has a cash flow conversion efficiency ratio of -0.442x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-16.89 Million ≈ $-1.82 Million USD) by net assets (Skr38.17 Million ≈ $4.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ACARIX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Acarix A/S - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Acarix A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Acarix A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acarix A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Projektengagemang Sweden AB (publ)
ST:PENG-B
|
0.038x |
|
Kingsmen Resources Ltd
V:KNG
|
-0.052x |
|
Datron AG
XETRA:DAR
|
-0.017x |
|
Klondike Gold Corp
V:KG
|
-0.008x |
|
Latch Inc
NASDAQ:LTCH
|
-0.134x |
|
Yao I Fabric Co Ltd
TWO:4430
|
0.002x |
|
Mestron Holdings
KLSE:0207
|
0.233x |
|
Buyung Poetra Sembada Tbk PT
JK:HOKI
|
0.209x |
Annual Cash Flow Conversion Efficiency for Acarix A/S (2014–2025)
The table below shows the annual cash flow conversion efficiency of Acarix A/S from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see ACARIX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr38.17 Million ≈ $4.11 Million |
Skr-48.38 Million ≈ $-5.21 Million |
-1.268x | -51.52% |
| 2024-12-31 | Skr75.70 Million ≈ $8.15 Million |
Skr-63.33 Million ≈ $-6.81 Million |
-0.837x | +46.65% |
| 2023-12-31 | Skr51.88 Million ≈ $5.58 Million |
Skr-81.37 Million ≈ $-8.76 Million |
-1.568x | -8.55% |
| 2022-12-31 | Skr51.83 Million ≈ $5.58 Million |
Skr-74.87 Million ≈ $-8.06 Million |
-1.445x | -202.56% |
| 2021-12-31 | Skr100.54 Million ≈ $10.82 Million |
Skr-48.01 Million ≈ $-5.17 Million |
-0.477x | -6.90% |
| 2020-12-31 | Skr82.14 Million ≈ $8.84 Million |
Skr-36.69 Million ≈ $-3.95 Million |
-0.447x | +23.17% |
| 2019-12-31 | Skr76.60 Million ≈ $8.24 Million |
Skr-44.53 Million ≈ $-4.79 Million |
-0.581x | -32.32% |
| 2018-12-31 | Skr87.88 Million ≈ $9.46 Million |
Skr-38.61 Million ≈ $-4.15 Million |
-0.439x | -39.74% |
| 2017-12-31 | Skr128.94 Million ≈ $13.88 Million |
Skr-40.54 Million ≈ $-4.36 Million |
-0.314x | -439.92% |
| 2016-12-31 | Skr155.52 Million ≈ $16.74 Million |
Skr-9.06 Million ≈ $-974.57K |
-0.058x | +91.81% |
| 2015-12-31 | Skr12.14 Million ≈ $1.31 Million |
Skr-8.63 Million ≈ $-928.83K |
-0.711x | +48.48% |
| 2014-12-31 | Skr15.12 Million ≈ $1.63 Million |
Skr-20.87 Million ≈ $-2.25 Million |
-1.380x | -- |
About Acarix A/S
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauri… Read more